Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Japanese (NIKKEI) Healthcare Sector Analysis

UpdatedDec 03, 2025
DataAggregated Company Financials
Companies206
  • 7D-1.0%
  • 3M9.0%
  • 1Y2.6%
  • YTD6.9%

In the last week, Healthcare has been flat. As for the the longer term, the industry is up 4.2% over the past 12 months. Earnings are forecast to grow by 11% annually.

Sector Valuation and Performance

Has the Japanese Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 03 Dec 2025JP¥70.1tJP¥38.5tJP¥2.8t16x25.5x1.8x
Fri, 31 Oct 2025JP¥65.8tJP¥38.2tJP¥2.7t15.4x24.6x1.7x
Sun, 28 Sep 2025JP¥63.5tJP¥38.2tJP¥2.7t15.9x23.7x1.7x
Tue, 26 Aug 2025JP¥64.3tJP¥38.2tJP¥2.7t16.1x24x1.7x
Thu, 24 Jul 2025JP¥63.2tJP¥38.1tJP¥2.6t15x24x1.7x
Sat, 21 Jun 2025JP¥61.8tJP¥38.1tJP¥2.6t14.6x23.4x1.6x
Mon, 19 May 2025JP¥61.8tJP¥37.9tJP¥2.6t14x23.4x1.6x
Wed, 16 Apr 2025JP¥58.9tJP¥37.5tJP¥2.4t14x24.6x1.6x
Fri, 14 Mar 2025JP¥62.7tJP¥37.5tJP¥2.4t15.3x26.3x1.7x
Sun, 09 Feb 2025JP¥64.0tJP¥37.2tJP¥2.2t15.6x29.4x1.7x
Tue, 07 Jan 2025JP¥66.3tJP¥36.7tJP¥2.2t16.7x29.6x1.8x
Thu, 05 Dec 2024JP¥68.6tJP¥36.7tJP¥2.2t15.9x30.6x1.9x
Sat, 02 Nov 2024JP¥70.6tJP¥36.3tJP¥2.0t17x34.5x1.9x
Mon, 30 Sep 2024JP¥70.8tJP¥36.0tJP¥2.0t17.6x35.7x2x
Wed, 28 Aug 2024JP¥73.6tJP¥36.0tJP¥2.0t17.9x37.1x2x
Fri, 26 Jul 2024JP¥69.0tJP¥35.1tJP¥1.8t17.9x37.4x2x
Sun, 23 Jun 2024JP¥64.7tJP¥35.3tJP¥1.9t17.8x34.6x1.8x
Tue, 21 May 2024JP¥65.8tJP¥35.3tJP¥1.9t17.2x35.2x1.9x
Thu, 18 Apr 2024JP¥62.8tJP¥34.7tJP¥1.9t17.2x32.2x1.8x
Sat, 16 Mar 2024JP¥67.5tJP¥35.1tJP¥2.0t18.3x34.4x1.9x
Mon, 12 Feb 2024JP¥65.5tJP¥35.1tJP¥2.1t18.8x31.9x1.9x
Wed, 10 Jan 2024JP¥64.8tJP¥35.0tJP¥2.2t18.8x30.1x1.8x
Fri, 08 Dec 2023JP¥63.8tJP¥35.0tJP¥2.2t17.7x29.6x1.8x
Sun, 05 Nov 2023JP¥61.4tJP¥34.7tJP¥2.2t17.3x28.2x1.8x
Tue, 03 Oct 2023JP¥62.4tJP¥34.5tJP¥2.3t17.8x27.5x1.8x
Thu, 31 Aug 2023JP¥64.3tJP¥34.5tJP¥2.3t17.9x28.4x1.9x
Sat, 29 Jul 2023JP¥63.5tJP¥34.1tJP¥2.3t18.4x27.4x1.9x
Mon, 26 Jun 2023JP¥66.3tJP¥33.9tJP¥2.3t18.7x28.6x2x
Wed, 24 May 2023JP¥65.2tJP¥33.9tJP¥2.3t18.7x28.2x1.9x
Fri, 21 Apr 2023JP¥61.6tJP¥33.5tJP¥2.3t17x26.8x1.8x
Sun, 19 Mar 2023JP¥60.0tJP¥33.5tJP¥2.3t16.8x26.1x1.8x
Tue, 14 Feb 2023JP¥59.8tJP¥33.4tJP¥2.3t16.4x26.2x1.8x
Thu, 12 Jan 2023JP¥58.7tJP¥32.4tJP¥2.2t15.8x27x1.8x
Sat, 10 Dec 2022JP¥63.5tJP¥32.4tJP¥2.2t16.1x29.2x2x
Price to Earnings Ratio

29.2x


Total Market Cap: JP¥63.5tTotal Earnings: JP¥2.2tTotal Revenue: JP¥32.4tTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Healthcare Sector Price to Earnings3Y Average 29x202320242025
Current Industry PE
  • Investors are pessimistic on the Japanese Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 25.4x which is lower than its 3-year average PE of 29.0x.
  • The industry is trading close to its 3-year average PS ratio of 1.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 8.2% per year over the last three years.
  • Revenues for these companies have grown 5.9% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare sector?

JP Market1.26%
Healthcare-0.96%
Life Sciences10.05%
Medical Equipment0.016%
Healthcare Services-0.44%
Pharma-1.15%
Biotech-2.02%
Healthtech-5.54%
Industry PE
  • Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio of 81.0x.
    • Analysts are expecting annual earnings growth of 5.8%, which is higher than its past year's earnings decline of 21.1% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 31% over the next 5 years.
  • This is better than its past earnings decline of 33% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 5.8% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
7741 HOYAJP¥23.66k2.1%
+JP¥167.5b		18.1%PE38.3x
4578 Otsuka HoldingsJP¥8.92k2.9%
+JP¥134.7b		-2.6%PE10.5x
4503 Astellas PharmaJP¥1.99k0.7%
+JP¥26.0b		23.0%PE28.6x
4502 Takeda PharmaceuticalJP¥4.47k0.3%
+JP¥22.1b		7.1%PE213.6x
4528 Ono PharmaceuticalJP¥2.14k1.6%
+JP¥15.5b		22.0%PE20.8x

Latest News

4528
JP¥2,144.00
Ono Pharmaceutical
7D
1.6%
1Y
22.0%

Ono Pharmaceutical (TSE:4528) Has Affirmed Its Dividend Of ¥40.00

Dec 02
Ono Pharmaceutical (TSE:4528) Has Affirmed Its Dividend Of ¥40.00
4523
JP¥4,737.00
Eisai
7D
-5.7%
1Y
1.2%
4507
JP¥2,640.00
Shionogi
7D
-3.4%
1Y
23.1%
4503
JP¥1,992.50
Astellas Pharma
7D
0.7%
1Y
23.0%
4502
JP¥4,472.00
Takeda Pharmaceutical
7D
0.3%
1Y
7.1%
2413
JP¥2,420.00
M3
7D
-6.3%
1Y
61.9%

At JP¥2,454, Is It Time To Put M3, Inc. (TSE:2413) On Your Watch List?

Dec 02
At JP¥2,454, Is It Time To Put M3, Inc. (TSE:2413) On Your Watch List?
4519
JP¥8,150.00
Chugai Pharmaceutical
7D
-2.5%
1Y
20.4%

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00

Dec 01
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00
4578
JP¥8,915.00
Otsuka Holdings
7D
2.9%
1Y
-2.6%

4578: Revenue Outlook And Regulatory Milestones Will Shape Near-Term Performance

Analysts have raised their price target for Otsuka Holdings from ¥9,400 to ¥9,579, citing expectations for improved revenue growth and profit margins. What's in the News Presentation of 12-month interim analysis results for sibeprenlimab, an investigational treatment for immunoglobulin A nephropathy (IgAN), at the 2025 American Society of Nephrology Kidney Week and simultaneous publication in The New England Journal of Medicine (Key Developments) Sibeprenlimab demonstrated a 54.3% placebo-adjusted reduction in proteinuria at 12 months in the Phase 3 VISIONARY trial.
4552
JP¥742.00
JCR Pharmaceuticals
7D
12.9%
1Y
2.1%

Revenues Not Telling The Story For JCR Pharmaceuticals Co., Ltd. (TSE:4552) After Shares Rise 36%

Nov 28
Revenues Not Telling The Story For JCR Pharmaceuticals Co., Ltd. (TSE:4552) After Shares Rise 36%
4568
JP¥3,714.00
Daiichi Sankyo Company
7D
-3.1%
1Y
-24.6%
7747
JP¥2,959.50
Asahi Intecc
7D
1.3%
1Y
11.0%
7733
JP¥2,036.50
Olympus
7D
-2.6%
1Y
-14.3%

Olympus' (TSE:7733) Upcoming Dividend Will Be Larger Than Last Year's

Nov 24
Olympus' (TSE:7733) Upcoming Dividend Will Be Larger Than Last Year's
7741
JP¥23,660.00
HOYA
7D
2.1%
1Y
18.1%

Is HOYA Corporation (TSE:7741) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 22
Is HOYA Corporation (TSE:7741) Expensive For A Reason? A Look At Its Intrinsic Value
4570
JP¥3,120.00
Immuno-Biological Laboratories
7D
81.5%
1Y
531.6%

Immuno-Biological Laboratories' (TSE:4570) Earnings Are Weaker Than They Seem

Nov 21
Immuno-Biological Laboratories' (TSE:4570) Earnings Are Weaker Than They Seem
4543
JP¥2,396.50
Terumo
7D
-1.4%
1Y
-22.7%

4543: US Imaging System Launch Will Drive Earnings Momentum Forward

Narrative Update on Terumo Analysts have lowered their price target for Terumo from ¥3,293 to ¥3,181. This reflects adjustments to profit margin estimates and an increase in the assumed discount rate, even as projected revenue growth has been revised upwards.
6869
JP¥1,461.00
Sysmex
7D
-6.7%
1Y
-54.0%

Earnings Miss: Sysmex Corporation Missed EPS By 6.2% And Analysts Are Revising Their Forecasts

Nov 09
Earnings Miss: Sysmex Corporation Missed EPS By 6.2% And Analysts Are Revising Their Forecasts